InterAx is a Swiss Biotech company spinoff from the Paul Scherrer Institute.
InterAx core expertise resides in engineering complexes of membrane protein and soluble protein. This allows InterAx to create protein biosensors specifically binding a chosen state of a membrane protein and to develop drug screening assays providing precise functional information or addressing currently undruggable targets.
Our products and services help pharmaceutical companies to develop better drugs and to reduce risks and costs in clinical trials by detecting early on potential adverse effects.
What we do
InterAx develops and markets drug-screening packages for the pharmaceutical industry which allow selection of drug candidates, quantification of cellular responses and prediction of drug action in the field of Functional selectivity (also known as “ligand bias”).